501 related articles for article (PubMed ID: 20818902)
1. Intensive blood-pressure control in hypertensive chronic kidney disease.
Appel LJ; Wright JT; Greene T; Agodoa LY; Astor BC; Bakris GL; Cleveland WH; Charleston J; Contreras G; Faulkner ML; Gabbai FB; Gassman JJ; Hebert LA; Jamerson KA; Kopple JD; Kusek JW; Lash JP; Lea JP; Lewis JB; Lipkowitz MS; Massry SG; Miller ER; Norris K; Phillips RA; Pogue VA; Randall OS; Rostand SG; Smogorzewski MJ; Toto RD; Wang X;
N Engl J Med; 2010 Sep; 363(10):918-29. PubMed ID: 20818902
[TBL] [Abstract][Full Text] [Related]
2. Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial.
Wright JT; Bakris G; Greene T; Agodoa LY; Appel LJ; Charleston J; Cheek D; Douglas-Baltimore JG; Gassman J; Glassock R; Hebert L; Jamerson K; Lewis J; Phillips RA; Toto RD; Middleton JP; Rostand SG;
JAMA; 2002 Nov; 288(19):2421-31. PubMed ID: 12435255
[TBL] [Abstract][Full Text] [Related]
3. Baseline characteristics of participants in the African American Study of Kidney Disease and Hypertension (AASK) Clinical Trial and Cohort Study.
Sika M; Lewis J; Douglas J; Erlinger T; Dowie D; Lipkowitz M; Lash J; Cornish-Zirker D; Peterson G; Toto R; Kusek J; Appel L; Kendrick C; Gassman J;
Am J Kidney Dis; 2007 Jul; 50(1):78-89, 89.e1. PubMed ID: 17591527
[TBL] [Abstract][Full Text] [Related]
4. Effect of ramipril vs amlodipine on renal outcomes in hypertensive nephrosclerosis: a randomized controlled trial.
Agodoa LY; Appel L; Bakris GL; Beck G; Bourgoignie J; Briggs JP; Charleston J; Cheek D; Cleveland W; Douglas JG; Douglas M; Dowie D; Faulkner M; Gabriel A; Gassman J; Greene T; Hall Y; Hebert L; Hiremath L; Jamerson K; Johnson CJ; Kopple J; Kusek J; Lash J; Lea J; Lewis JB; Lipkowitz M; Massry S; Middleton J; Miller ER; Norris K; O'Connor D; Ojo A; Phillips RA; Pogue V; Rahman M; Randall OS; Rostand S; Schulman G; Smith W; Thornley-Brown D; Tisher CC; Toto RD; Wright JT; Xu S;
JAMA; 2001 Jun; 285(21):2719-28. PubMed ID: 11386927
[TBL] [Abstract][Full Text] [Related]
5. Long-term effects of renin-angiotensin system-blocking therapy and a low blood pressure goal on progression of hypertensive chronic kidney disease in African Americans.
Appel LJ; Wright JT; Greene T; Kusek JW; Lewis JB; Wang X; Lipkowitz MS; Norris KC; Bakris GL; Rahman M; Contreras G; Rostand SG; Kopple JD; Gabbai FB; Schulman GI; Gassman JJ; Charleston J; Agodoa LY;
Arch Intern Med; 2008 Apr; 168(8):832-9. PubMed ID: 18443258
[TBL] [Abstract][Full Text] [Related]
6. Effects of valsartan on progression of kidney disease in Japanese hypertensive patients with advanced, predialysis, chronic kidney disease: Kanagawa Valsartan Trial (KVT).
Yasuda T; Endoh M; Suzuki D; Yoshimura A; Ideura T; Tamura K; Kamata K; Toya Y; Umemura S; Kimura K;
Hypertens Res; 2013 Mar; 36(3):240-6. PubMed ID: 23154591
[TBL] [Abstract][Full Text] [Related]
7. BP and Renal Outcomes in Diabetic Kidney Disease: The Veterans Affairs Nephropathy in Diabetes Trial.
Leehey DJ; Zhang JH; Emanuele NV; Whaley-Connell A; Palevsky PM; Reilly RF; Guarino P; Fried LF;
Clin J Am Soc Nephrol; 2015 Dec; 10(12):2159-69. PubMed ID: 26482258
[TBL] [Abstract][Full Text] [Related]
8. Arterial hypertension and proteinuria in pediatric chronic kidney disease.
Simonetti GD; Bucher BS; Tschumi S; Lava SA; Bianchetti MG
Minerva Pediatr; 2012 Apr; 64(2):171-82. PubMed ID: 22495191
[TBL] [Abstract][Full Text] [Related]
9. APOL1 risk variants, race, and progression of chronic kidney disease.
Parsa A; Kao WH; Xie D; Astor BC; Li M; Hsu CY; Feldman HI; Parekh RS; Kusek JW; Greene TH; Fink JC; Anderson AH; Choi MJ; Wright JT; Lash JP; Freedman BI; Ojo A; Winkler CA; Raj DS; Kopp JB; He J; Jensvold NG; Tao K; Lipkowitz MS; Appel LJ; ;
N Engl J Med; 2013 Dec; 369(23):2183-96. PubMed ID: 24206458
[TBL] [Abstract][Full Text] [Related]
10. Effects of intensive blood pressure lowering on the progression of chronic kidney disease: a systematic review and meta-analysis.
Lv J; Ehteshami P; Sarnak MJ; Tighiouart H; Jun M; Ninomiya T; Foote C; Rodgers A; Zhang H; Wang H; Strippoli GF; Perkovic V
CMAJ; 2013 Aug; 185(11):949-57. PubMed ID: 23798459
[TBL] [Abstract][Full Text] [Related]
11. Strict blood-pressure control and progression of renal failure in children.
; Wühl E; Trivelli A; Picca S; Litwin M; Peco-Antic A; Zurowska A; Testa S; Jankauskiene A; Emre S; Caldas-Afonso A; Anarat A; Niaudet P; Mir S; Bakkaloglu A; Enke B; Montini G; Wingen AM; Sallay P; Jeck N; Berg U; Caliskan S; Wygoda S; Hohbach-Hohenfellner K; Dusek J; Urasinski T; Arbeiter K; Neuhaus T; Gellermann J; Drozdz D; Fischbach M; Möller K; Wigger M; Peruzzi L; Mehls O; Schaefer F
N Engl J Med; 2009 Oct; 361(17):1639-50. PubMed ID: 19846849
[TBL] [Abstract][Full Text] [Related]
12. Blood pressure control, drug therapy, and kidney disease.
Contreras G; Greene T; Agodoa LY; Cheek D; Junco G; Dowie D; Lash J; Lipkowitz M; Miller ER; Ojo A; Sika M; Wilkening B; Toto RD;
Hypertension; 2005 Jul; 46(1):44-50. PubMed ID: 15897360
[TBL] [Abstract][Full Text] [Related]
13. Effects of blood pressure level on progression of diabetic nephropathy: results from the RENAAL study.
Bakris GL; Weir MR; Shanifar S; Zhang Z; Douglas J; van Dijk DJ; Brenner BM;
Arch Intern Med; 2003 Jul; 163(13):1555-65. PubMed ID: 12860578
[TBL] [Abstract][Full Text] [Related]
14. Angiotensin-converting enzyme inhibitors and progression of nondiabetic renal disease. A meta-analysis of patient-level data.
Jafar TH; Schmid CH; Landa M; Giatras I; Toto R; Remuzzi G; Maschio G; Brenner BM; Kamper A; Zucchelli P; Becker G; Himmelmann A; Bannister K; Landais P; Shahinfar S; de Jong PE; de Zeeuw D; Lau J; Levey AS
Ann Intern Med; 2001 Jul; 135(2):73-87. PubMed ID: 11453706
[TBL] [Abstract][Full Text] [Related]
15. Renal outcomes in hypertensive Black patients at high cardiovascular risk.
Weir MR; Bakris GL; Weber MA; Dahlof B; Devereux RB; Kjeldsen SE; Pitt B; Wright JT; Kelly RY; Hua TA; Hester RA; Velazquez E; Jamerson KA
Kidney Int; 2012 Mar; 81(6):568-76. PubMed ID: 22189843
[TBL] [Abstract][Full Text] [Related]
16. Effect of Blood Pressure Control on Long-Term Risk of End-Stage Renal Disease and Death Among Subgroups of Patients With Chronic Kidney Disease.
Ku E; Sarnak MJ; Toto R; McCulloch CE; Lin F; Smogorzewski M; Hsu CY
J Am Heart Assoc; 2019 Aug; 8(16):e012749. PubMed ID: 31411082
[TBL] [Abstract][Full Text] [Related]
17. Progression of chronic kidney disease: the role of blood pressure control, proteinuria, and angiotensin-converting enzyme inhibition: a patient-level meta-analysis.
Jafar TH; Stark PC; Schmid CH; Landa M; Maschio G; de Jong PE; de Zeeuw D; Shahinfar S; Toto R; Levey AS;
Ann Intern Med; 2003 Aug; 139(4):244-52. PubMed ID: 12965979
[TBL] [Abstract][Full Text] [Related]
18. The relationship between magnitude of proteinuria reduction and risk of end-stage renal disease: results of the African American study of kidney disease and hypertension.
Lea J; Greene T; Hebert L; Lipkowitz M; Massry S; Middleton J; Rostand SG; Miller E; Smith W; Bakris GL
Arch Intern Med; 2005 Apr; 165(8):947-53. PubMed ID: 15851648
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of benazepril for advanced chronic renal insufficiency.
Hou FF; Zhang X; Zhang GH; Xie D; Chen PY; Zhang WR; Jiang JP; Liang M; Wang GB; Liu ZR; Geng RW
N Engl J Med; 2006 Jan; 354(2):131-40. PubMed ID: 16407508
[TBL] [Abstract][Full Text] [Related]
20. Rationale and design of the Eplerenone combination Versus conventional Agents to Lower blood pressure on Urinary Antialbuminuric Treatment Effect (EVALUATE) trial: a double-blinded randomized placebo-controlled trial to evaluate the antialbuminuric effects of an aldosterone blocker in hypertensive patients with albuminuria.
Ando K; Ohtsu H; Arakawa Y; Kubota K; Yamaguchi T; Nagase M; Yamada A; Fujita T;
Hypertens Res; 2010 Jun; 33(6):616-21. PubMed ID: 20379190
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
